CPI-006 plus standard of care versus placebo plus standard of care in hospitalized adults with mild to moderate COVID-19

Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing mopadulimab plus standard of care with placebo plus standard of care (2 arms). Primary endpoint: Proportion of participants alive and free from respiratory deterioration through Day 28. Started Feb 2021; status: terminated.